Skip to search formSkip to main contentSkip to account menu

0.2 ML ocriplasmin 2.5 MG/ML Injection

Known as: ocriplasmin 0.5 MG in 0.2 ML Injection, OCRIPLASMIN 0.5MG/0.2ML OPH INJ, OCRIPLASMIN 0.5MG/0.2ML INJ,OPH [VA Product] 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (1)

0.2 ML ocriplasmin 2.5 MG/ML Injection [Jetrea]
InjectionPeptide Hydrolasesocriplasmin

Broader (1)

OPHTHALMICS,OTHER

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications
Purpose: To investigate predictors of success, visual outcomes, and complications of intravitreal ocriplasmin for the treatment… 
Review
2018
Review
2018
Updated Cost-Effectiveness of Intravitreal Ocriplasmin for Vitreomacular Adhesion and Macular Hole.
BACKGROUND AND OBJECTIVE The purpose of this study is to provide an updated assessment of cost-efficacy of intravitreal… 
2018
2018
Multimodal imaging of macular subretinal deposits following intravitreal ocriplasmin injection
2017
2017
Stellenwert von Ocriplasmin bei der Therapie der vitreomakulären Traktion mit und ohne Makulaforamen – erste klinische Erfahrungen
Zusammenfassung Hintergrund Bei der vitreomakulären Traktion (VMT) besteht eine abnormal starke Adhärenz zwischen Netzhaut und… 
2017
2017
Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice
PurposeTo assess treatment effects following intravitreal injection of ocriplasmin for vitreomacular traction (VMT), with or… 
2017
2017
LONGITUDINAL MICROPERIMETRY EVALUATION AFTER INTRAVITREAL OCRIPLASMIN INJECTION FOR VITREOMACULAR TRACTION
Purpose: To determine whether improvements in microperimetry testing are associated with anatomic resolution after ocriplasmin… 
Review
2016
Review
2016
Pharmakologische Vitreolyse mit Ocriplasmin als Behandlungsoption bei symptomatischer fokaler vitreomakulärer Traktion mit oder ohne Makulaforamen (≤400 μm) im Vergleich zur transkonjunktivalen…
ZusammenfassungHintergrundDie Behandlung einer vitreomakulären Traktion (VMT) mit Ocriplasmin (Jetrea®) war in großen Phase-3… 
2016
2016
Biomechanical Properties of the Internal Limiting Membrane after Intravitreal Ocriplasmin Treatment
Purpose: To assess the stiffness of the human internal limiting membrane (ILM) and evaluate potential changes of mechanical… 
2016
2016
Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study
PurposeTo evaluate prospectively the anatomical and functional results after ocriplasmin injection in patients with vitreomacular… 
Review
2015
Review
2015
OUTER RETINA REFLECTIVITY CHANGES ON SD-OCT AFTER INTRAVITREAL OCRIPLASMIN FOR VITREOMACULAR TRACTION AND MACULAR HOLE
Purpose: To report initial experience with intravitreal ocriplasmin (IVO) and to describe outer retina reflectivity changes… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)